The US Food and Drug Administration has approved the S(+) enantiomer of ketamine under the new generic name eskatamine1 to be used as a fast acting treatment for depression (archived). The dissociative anesthetic drug is being marketed as a fast acting nasal spray offering relief within hours. Attached to the approval are conditions that this dissociative experience only be administered at select clinics with individual doses costing 900 USD per hit or 7000 USD for a month of biweekly doses as recommended by the label instructions.
Trade name: Spravato ↩